Cargando…
Development and Validation of the Amphetamine-Type Stimulants Motive Questionnaire in a Clinical Population
Approximately 35.7 million people world-wide use amphetamine-type stimulants (ATS) leading to a high demand for effective treatment. Understanding the motives behind ATS use is a necessary basis for preventive and therapeutic treatment. The objective of this study is to develop the Amphetamine-Type...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622292/ https://www.ncbi.nlm.nih.gov/pubmed/28993742 http://dx.doi.org/10.3389/fpsyt.2017.00183 |
_version_ | 1783267873288880128 |
---|---|
author | Thurn, Daniela Kuntsche, Emmanuel Weber, Jennifer Anna Wolstein, Jörg |
author_facet | Thurn, Daniela Kuntsche, Emmanuel Weber, Jennifer Anna Wolstein, Jörg |
author_sort | Thurn, Daniela |
collection | PubMed |
description | Approximately 35.7 million people world-wide use amphetamine-type stimulants (ATS) leading to a high demand for effective treatment. Understanding the motives behind ATS use is a necessary basis for preventive and therapeutic treatment. The objective of this study is to develop the Amphetamine-Type stimulants Motive Questionnaire (AMQ) and to confirm its construct and concurrent validity in respect to the first and the latest month of ATS use based on answers of 233 patients with ATS disorders (74.2% male; mean age: 31.1 years). Confirmatory factor analyses were employed to test for the construct validity of the AMQ. Nested models of confirmatory factor analyses with increasing constraints for gender and age were estimated to test the equivalence of the factor structure in different subgroups. Independent sample t-tests were conducted to test for mean differences in the motive dimensions. A structural equation model was estimated to confirm the concurrent validity using the latent four motive factors (i.e., enhancement, coping, social, and conformity motives) as independent variables and frequency of ATS use in the first and the latest month of use as a dependent variable. The results confirmed the AMQ’s four-dimensional factor structure in general, and across gender and age groups for both periods of time. Men (first month: M = 4.21, SD = 0.75; latest month: M = 3.86, SD = 0.93) use ATS more frequently due to enhancement motives than women (first month: M = 3.85, SD = 1.12; latest month: M = 3.46, SD = 1.29) at both periods of time [first month: t(77) = −2.33, p = 0.022; latest month: t(80) = −2.19, p = 0.031]. Structural equation modeling confirmed an association between coping motives and use frequency, for both periods of time (first and latest month: β = 0.32, p < 0.001), as well as between social motives and frequency of use for the latest month of use (β = 0.30, p < 0.01). To conclude, the AMQ is a valid and reliable instrument for assessing motives of ATS use in a clinical population. It can provide important insights into the motivational structure of the first and latest months of ATS use which are useful for preventive and therapeutic treatments as well as the development of abstinence skills. |
format | Online Article Text |
id | pubmed-5622292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56222922017-10-09 Development and Validation of the Amphetamine-Type Stimulants Motive Questionnaire in a Clinical Population Thurn, Daniela Kuntsche, Emmanuel Weber, Jennifer Anna Wolstein, Jörg Front Psychiatry Psychiatry Approximately 35.7 million people world-wide use amphetamine-type stimulants (ATS) leading to a high demand for effective treatment. Understanding the motives behind ATS use is a necessary basis for preventive and therapeutic treatment. The objective of this study is to develop the Amphetamine-Type stimulants Motive Questionnaire (AMQ) and to confirm its construct and concurrent validity in respect to the first and the latest month of ATS use based on answers of 233 patients with ATS disorders (74.2% male; mean age: 31.1 years). Confirmatory factor analyses were employed to test for the construct validity of the AMQ. Nested models of confirmatory factor analyses with increasing constraints for gender and age were estimated to test the equivalence of the factor structure in different subgroups. Independent sample t-tests were conducted to test for mean differences in the motive dimensions. A structural equation model was estimated to confirm the concurrent validity using the latent four motive factors (i.e., enhancement, coping, social, and conformity motives) as independent variables and frequency of ATS use in the first and the latest month of use as a dependent variable. The results confirmed the AMQ’s four-dimensional factor structure in general, and across gender and age groups for both periods of time. Men (first month: M = 4.21, SD = 0.75; latest month: M = 3.86, SD = 0.93) use ATS more frequently due to enhancement motives than women (first month: M = 3.85, SD = 1.12; latest month: M = 3.46, SD = 1.29) at both periods of time [first month: t(77) = −2.33, p = 0.022; latest month: t(80) = −2.19, p = 0.031]. Structural equation modeling confirmed an association between coping motives and use frequency, for both periods of time (first and latest month: β = 0.32, p < 0.001), as well as between social motives and frequency of use for the latest month of use (β = 0.30, p < 0.01). To conclude, the AMQ is a valid and reliable instrument for assessing motives of ATS use in a clinical population. It can provide important insights into the motivational structure of the first and latest months of ATS use which are useful for preventive and therapeutic treatments as well as the development of abstinence skills. Frontiers Media S.A. 2017-09-25 /pmc/articles/PMC5622292/ /pubmed/28993742 http://dx.doi.org/10.3389/fpsyt.2017.00183 Text en Copyright © 2017 Thurn, Kuntsche, Weber and Wolstein. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Thurn, Daniela Kuntsche, Emmanuel Weber, Jennifer Anna Wolstein, Jörg Development and Validation of the Amphetamine-Type Stimulants Motive Questionnaire in a Clinical Population |
title | Development and Validation of the Amphetamine-Type Stimulants Motive Questionnaire in a Clinical Population |
title_full | Development and Validation of the Amphetamine-Type Stimulants Motive Questionnaire in a Clinical Population |
title_fullStr | Development and Validation of the Amphetamine-Type Stimulants Motive Questionnaire in a Clinical Population |
title_full_unstemmed | Development and Validation of the Amphetamine-Type Stimulants Motive Questionnaire in a Clinical Population |
title_short | Development and Validation of the Amphetamine-Type Stimulants Motive Questionnaire in a Clinical Population |
title_sort | development and validation of the amphetamine-type stimulants motive questionnaire in a clinical population |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622292/ https://www.ncbi.nlm.nih.gov/pubmed/28993742 http://dx.doi.org/10.3389/fpsyt.2017.00183 |
work_keys_str_mv | AT thurndaniela developmentandvalidationoftheamphetaminetypestimulantsmotivequestionnaireinaclinicalpopulation AT kuntscheemmanuel developmentandvalidationoftheamphetaminetypestimulantsmotivequestionnaireinaclinicalpopulation AT weberjenniferanna developmentandvalidationoftheamphetaminetypestimulantsmotivequestionnaireinaclinicalpopulation AT wolsteinjorg developmentandvalidationoftheamphetaminetypestimulantsmotivequestionnaireinaclinicalpopulation |